Rakovina Therapeutics Inc · TSXV:RKV

Rakovina Therapeutics — Investor Presentation (May 2022)

19 slides from Rakovina Therapeutics's investor presentation, May 2022

  1. Slide 1: Revolutionizing Cancer Treatment with DNA Damage Response Inhibitor Technology

    TSX-V: RKV Revolutionizing Cancer Treatment with DNA Damage Response Inhibitor Technology Corporate Presentation May 2022

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Certain forward-looking statements contained herein constitute “forward- receipts as disclosed herein; additional sources of funding, including looking information” (collectively, “forward-looking information”) within the grants and funding from partners; the Company’s abi

  3. Slide 3: Recent Highlights

    TSX-V: RKV Recent Highlights • Selected to join a three-year CDN1.3 million (US$975,000) research program funded by St. Baldrick’s Foundation aimed at developing new treatments for childhood and adolescent bone cancer • Presented pre-clinical research results at peer- reviewed scientific meetings •

  4. Slide 4: Cancer is Still a Leading Cause of Death; We Need Better Treatments

    Cancer is Still a Leading Cause of Death; We Need Better Treatments • With an aging western population, cancer occurrences are expected to rise • Chemotherapy is the current gold standard treatment, also kills many healthy cells, causing considerable patient health issues • Although many cancers can

  5. Slide 5: Rakovina Therapeutics' DNA Damage Response Inhibitor (DDRi) Technology

    Rakovina Therapeutics’ DNA Damage Response Inhibitor (DDRi) Technology Can Potentially Reduce the Onset and Reoccurrence of Several Cancers Note: Image is for illustrative purposes only. Health claims have yet to be authorized by any regulatory agency and are only used to express the potential of th

  6. Slide 6: DNA Damage and Cancer

    DNA Damage and Cancer • Tens of thousands of DNA damaging events occur in our cells every day • DNA Damage Response (DDR) is a collection of processes within our cells that identify and correct DNA damage • Many cancers harbor a defect in natural DDR mechanisms that allow tumor cells to evade the hu

  7. Slide 7: Exploits Cancer's Achilles' Heel

    Many cancers hijack DDR system defects allowing tumors to Normal Cell develop and grow unchecked Pre-cancerous Rakovina DDRi Full compliment of DNA repair Cell Mutation = DDR-loss Exploits Cancer’s pathways A B A B of pathway “A” “Achilles’ Heel” • Cancer cells with a DDR Some cancers become heavily

  8. Slide 8: Big-Pharma Invests Over $25 B into DDRi

    Big-Pharma Invests Over $25 B into DDRi Target Firm Amount Year Type Details $14.0B 2016 Acq. Phase 3 $5.1B 2019 Acq. FDA Approved DNA-damage response is a top research priority (2020 Annual Report) $3.0B 2020 Invest. Collaboration Collaboration $3.0B 2020 Invest. Option License $1.3B 2021 Invest. C

  9. Slide 9: Major Cancer Markets with Unmet Medical Needs are an Opportunity for Rakovina DDRi

    Major Cancer Markets with Unmet Medical Needs are an Opportunity for Rakovina DDRi Triple Negative Prostate Ovarian Breast Cancer Cancer Cancer $13.0B $12.8B $6.7B Rakovina’s Strategy: Build upon the success of Poly (ADP-Ribrose) Polymerase inhibitors (PARPi), the 1st “blockbuster” DDR, by, developi

  10. Slide 10: Rakovina Therapeutics Intellectual Property Portfolio

    Rakovina Therapeutics Intellectual Property Portfolio kt-2000 kt-3000 kt-4000 Next-generation PARPi Dual-function DDRi DNA-damaging DDRi Owned patents and patent- Exclusive option to patent- Exclusive option to patent- pending applications extend pending applications extend pending applications exte

  11. Slide 11: UBC Collaboration

    UBC Collaboration • Lead candidate optimization and preclinical development conducted in collaboration with the University of British Columbia • “In-house” team of five dedicated researchers under the direction of Prof. Mads Daugaard, a recognized leader in the DDRi field • State-of-the-Art faciliti

  12. Slide 12: Current Status and Next Steps

    Current Status and Next Steps • Optimizing lead candidates for advancement to human clinical trials • Most promising lead candidates have advanced to in vivo toxicology and pharmacokinetic studies • Continued medicinal chemistry/rational drug design • Disease-specific animal models planned to suppor

  13. Slide 13: Unlocking Value in New Therapies

    Unlocking Value in New Therapies USD millions Average Pharmaceutical $1,119M Program Value (BayBridge BIO 2019) $248M $88M $15M May 2022 13 ©Rakovina Therapeutics Inc. 13

  14. Slide 14: Scientific & Drug Development Leadership

    Scientific & Drug Development Leadership Jeffrey Bacha, BSc, MBA 25+ year healthcare and life science executive. Extensive experience in securing public and private funding and building strong Executive Chairman scientific teams to meet ambitious business goals. Mads Daugaard, PhD Recognized leader

  15. Slide 15: Capitalization (March 31, 2022)

    Capitalization (March 31, 2022) Rakovina Therapeutics Inc. was initially capitalized with ~$4.7 million working capital through an amalgamation with TSX-V listed Vincero Capital Corp. and concurrent private placement in a CPC qualifying transaction. Common shares outstanding 69,829,500 Escrowed comm

  16. Slide 16: Selected Financial Results

    Selected Financial Results For the year ended As at Statements of net loss and December 31, 2021 Selected Financial December 31, 2021 comprehensive loss data: $ Information $ Cash & cash equivalents 2,811,541 Research & Development 1,502,439 Working capital 2,956,994 General and administrative 971,8

  17. Slide 17: Communicating our Progress

    Communicating our Progress Peer Reviewed Scientific & Business Conference Events (2021-22) Upcoming Events • AACR Sarcoma Meeting (May 2022) – kt-3000 Series data Recent Events ✓ JCA-AACR Precision Medicine International Conference (Sept 2021) ✓ AACR-NCI-EORTC International Conference on Molecular T

  18. Slide 18: Investment Thesis

    Investment Thesis • Diverse portfolio based on three novel series of pre-clinical drug candidates • Highly efficient research model in collaboration with University of British Columbia • Recognition by peer-reviewed scientific meetings and leading grant funding agency • Well capitalized to achieve n

  19. Slide 19: Contact

    Rakovina David Hyman, CFO Therapeutics Inc. (403) 613-1453 | [email protected] Joseph Garcia, Partner, Blake Cassels and Graydon LLP Legal Advisors (604) 631-3307 | [email protected] Davidson & Company LLP Auditor Contact (604) 900-9230 | [email protected] Odyssey Tr

Rakovina Therapeutics — Investor Presentation (May 2022) on 6ix